Natera Completes Enrollment in Heart Transplant Trial Challenging Biopsy Standard — Natera, Inc.

Event summary

Natera completed enrollment in the ACES-EMB trial, a randomized study evaluating its Prospera Heart test as an alternative to invasive biopsies for heart transplant rejection monitoring.
The trial enrolled over 300 patients across 17 U.S. transplant centers, with participants followed for 12 months post-randomization.
Positive results could shift the standard of care from invasive procedures to non-invasive molecular monitoring for ~4,500 annual U.S. heart transplants.

The big picture

The trial represents a pivotal moment in heart transplantation, where non-invasive donor-derived cell-free DNA (dd-cfDNA) testing could displace costly and risky biopsy procedures. Success would align with broader trends toward precision medicine and molecular diagnostics across organ health. Natera’s ability to scale this approach hinges on both clinical validation and payer acceptance of the cost-effective alternative.

What we're watching

Clinical Validation: Whether ACES-EMB results will demonstrate Prospera’s non-invasive approach delivers comparable clinical outcomes to biopsies.
Regulatory Pathway: The pace at which Natera can secure approvals if trial data supports replacing invasive monitoring with dd-cfDNA testing.
Market Adoption: How quickly transplant centers would transition from biopsy-based care to molecular surveillance if evidence supports the shift.